Lymph node metastasis: Ultrasmall superparamagnetic iron oxide-enhanced MR imaging versus PET/CT in a rabbit model

Radiology

Volumn 242, Issue 1, 2007, Pages 137-143

  Choi, Seung Hong ^a   Moon, Woo Kyung ^a   Hong, Ju Hee ^b   Son, Kyu Ri ^a   Cho, Nariya ^a   Kwon, Bae Ju ^a   Lee, Jong Jin ^a   Chung, June Key ^a   Min, Hye Sook ^a   Park, Seong Ho ^c  

^a Seoul National University Hospital   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCRYSTALLINE IRON OXIDE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPARATUS; ARTICLE; CANCER MODEL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EVALUATION; HISTOLOGY; HISTOPATHOLOGY; ILIACL LYMPH NODE; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; LYMPH NODE; LYMPH NODE METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RABBIT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ANIMALS; CARCINOMA; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; IMAGE ENHANCEMENT; IRON; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; OXIDES; POSITRON-EMISSION TOMOGRAPHY; RABBITS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33845602056     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2421060093     Document Type: Article

References (26)

1. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med 2004;45:1509-1518.
2. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-1209.
3. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-1019.
4. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229:526-533.
5. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797-1803.
6. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231:65-72.
7. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99:294-300.
8. Vassallo P, Matei C, Heston WD, McLachlan SJ, Koutcher JA, Castellino RA. Characterization of reactive versus tumor-bearing lymph nodes with interstitial magnetic resonance lymphography in an animal model. Invest Radiol 1995;30:706-711.
9. Vassallo P, Matei C, Heston WD, McLachlan SJ, Koutcher JA, Castellino RA. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology 1994;193:501-506.
10. Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography: study of a high-efficiency lymphotrophic agent. Radiology 1994;191:225-230.
11. Bengele HH, Palmacci S, Rogers J, Jung CW, Crenshaw J, Josephson L. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration. Magn Reson Imaging 1994;12:433-442.
12. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493.
13. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499.
14. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003;228:777-788.
15. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings-initial observations. Radiology 2004;231:91-99.
16. Dunne AA, Mandic R, Ramaswamy A, et al. Lymphogenic metastatic spread of auricular VX2 carcinoma in New Zealand white rabbits. Anticancer Res 2002;22:3273-3279.
17. Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 2002;13:264-268.
18. Harisinghani MG, Dixon WT, Saksena MA, et al. MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. RadioGraphics 2004;24:867-878.
19. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. RadioGraphics 2005;25:1031-1043.
20. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507.
21. Hanley JA, McNeil BJ. A method comparing the areas under receiver operator characteristic curves derived from the same cases. Radiology 1983;148:839-843.
22. Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics 1992;48:577-585.
23. Zhou X, Obuchowski NA, McClith DK. Statistical methods in diagnostic medicine. New York, NY: Wiley, 2002; 165-171.
24. Lee AS, Weissleder R, Brady TJ, Wittenberg J. Lymph nodes: microstructural anatomy at MR imaging. Radiology 1991;178:519-522.
25. Koh DM, Cook GJ, Husband JE. New horizons in oncologic imaging. N Engl J Med 2003;348:2487-2488.
26. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Barentsz JO. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol 2004;14:1707-1712.